November 14, 2024 10:56 AM EST
News Briefing

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

ENDPOINTS

Plus, news about Al­lo­gene, Telix, Cull­gen, Pul­ma­trix, Gilead, In­no­coll, Durect and Sen­sei:

Zai Lab’s $200M of­fer­ing: The Shang­hai-based drug­mak­er is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times